| DC Field | Value | Language |
|---|
| dc.contributor.author | Kolesnichenko, P. D. | - |
| dc.contributor.author | Gudyrev, O. S. | - |
| dc.contributor.author | Zhuchenko, M. A. | - |
| dc.contributor.author | Zhernakova, N. I. | - |
| dc.contributor.author | Faitelson, A. V. | - |
| dc.date.accessioned | 2019-08-21T08:23:33Z | - |
| dc.date.available | 2019-08-21T08:23:33Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Evaluation of carbamylated darbepoetin acute toxicity / P.D. Kolesnichenko [et al.] // International Journal of Research in Pharmaceutical Sciences. - 2018. - Vol.9, №3.-P. 725-730. - DOI: https://doi.org/10.26452/ijrps.v9i3.1554. - Refer.: p. 729-730. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/26824 | - |
| dc.description.abstract | Carbamylated darbepoetin is a promising pharmacological agent with universal cytoprotective activity. To assess the acute toxicity, the drug was administered to white laboratory mice and white laboratory rats subcutaneously (from 1000 to 5000 μg / kg) and intravenously (500 to 2500 μg / kg). There was no lethality and no phenotypic changes (including from the red blood sprout) in both species of animals. The study showed that the drug carbamylated darbepoetin (Pharmapark, Russia) belongs to the IV class of low-toxic drugs | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | pharmacological agents | ru |
| dc.subject | erythropoietin | ru |
| dc.subject | carbamylated darbepoetin | ru |
| dc.subject | rats | ru |
| dc.subject | hypoxia | ru |
| dc.subject | acute toxicity | ru |
| dc.title | Evaluation of carbamylated darbepoetin acute toxicity | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
